Press Releases Stay on top of the latest news from Poseida Therapeutics. Learn about our leading-edge cell and gene therapy programs, from new discoveries to clinical trials, and get the most recent investor news. IR Sub Menu Investors & Media Corporate Profile Press Releases Events & Presentations Publications Year None2021202020192018201720162015 Poseida Therapeutics to Present CAR-T Manufacturing Process Optimization Data at CAR-TCR Digital Week 2020 09/16/2020 Poseida Therapeutics Reports Operational Update and Financial Results for Second Quarter and First Half of 2020 08/20/2020 Poseida Therapeutics Appoints Harry J. Leonhardt, Esq. as General Counsel 07/16/2020 Poseida Therapeutics Announces Pricing of Initial Public Offering 07/09/2020 Poseida Therapeutics Raises $110 Million in Series D Financing 06/25/2020 Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer 05/20/2020 Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting 11/05/2019 Poseida Therapeutics Appoints Kerry Ingalls as Chief Operating Officer 10/10/2019 Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma 05/13/2019 Poseida Therapeutics Raises $142 Million in Series C Financing 04/22/2019 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Next page next › Last page last » Displaying 21 - 30 of 70
Year None2021202020192018201720162015 Poseida Therapeutics to Present CAR-T Manufacturing Process Optimization Data at CAR-TCR Digital Week 2020 09/16/2020 Poseida Therapeutics Reports Operational Update and Financial Results for Second Quarter and First Half of 2020 08/20/2020 Poseida Therapeutics Appoints Harry J. Leonhardt, Esq. as General Counsel 07/16/2020 Poseida Therapeutics Announces Pricing of Initial Public Offering 07/09/2020 Poseida Therapeutics Raises $110 Million in Series D Financing 06/25/2020 Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer 05/20/2020 Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting 11/05/2019 Poseida Therapeutics Appoints Kerry Ingalls as Chief Operating Officer 10/10/2019 Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma 05/13/2019 Poseida Therapeutics Raises $142 Million in Series C Financing 04/22/2019 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Next page next › Last page last » Displaying 21 - 30 of 70
Poseida Therapeutics to Present CAR-T Manufacturing Process Optimization Data at CAR-TCR Digital Week 2020 09/16/2020
Poseida Therapeutics Reports Operational Update and Financial Results for Second Quarter and First Half of 2020 08/20/2020
Poseida Therapeutics Announces Dosing of First Patient in Phase 1 Clinical Trial of P-PSMA-101 Autologous CAR-T for Metastatic Castration-Resistant Prostate Cancer 05/20/2020
Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting 11/05/2019
Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma 05/13/2019